Global Orally Disintegrating Tablet Market Overview:
An Orally Disintegrating Tablet is a drug dosage form available for a limited range of over-the-counter and prescription medications. It differs from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. ODTs dissolve or disintegrate in the mouth without water within sixty seconds when placed on the patient’s tongue. They’re ideal for patients such as older adults or children who have difficulty swallowing traditional oral capsules or tablets and those with mental illness. According to HTF MI, the Global Orally Disintegrating Tablet market is expected to see growth rate of 11.2%
Market Highlights:
On 26 Dec. 2018, Neos Therapeutics, Inc., announced that it has entered into a confidential settlement and licensing agreement with Teva Pharmaceuticals USA, Inc. to resolve all ongoing litigation involving Neos’ patents protecting its Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets and Teva’s Abbreviated New Drug Application (ANDA) filed with the U.S. Food and Drug Administration to market a generic version of that product.
Market driver;
•The Rising Geriatric Population Worldwide
• Increasing Number of Mentally Challenged People
• The Advantages Offered by the Orally Disintegrating Drugs
Restraints;
• The High Cost of the Production
Opportunities;
• The emergence of Next Generation ODTS
• The Emerging Demand from Developing Countries
Challenge;
• Mechanical strength and disintegration time
• Taste masking
• Janssen Pharmaceutica (Belgium)
